Masashi Miyamoto, Kyowa Kirin CEO
July 15, 2022 10:38 AM EDT
R&D

Ky­owa Kirin pulls the plug on drug de­vel­op­ment for suc­ces­sor to Parkin­son's drug Nouri­anz

Paul Schloesser

Associate Editor

Three years af­ter Japan’s Ky­owa Kirin se­cured FDA ap­proval for an add-on ther­a­py to lev­odopa in Parkin­son’s, the com­pa­ny has scrapped its po­ten­tial suc­ces­sor. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times